Skip to content

PATENCY OF THE;GEM MICROVASCULAR ANASTOMOTIC COUPLER SYSTEM* ;IN CORONARY ARTERY BYPASS GRAFTING;Pilot Study

PATENCY OF THE;GEM MICROVASCULAR ANASTOMOTIC COUPLER SYSTEM* ;IN CORONARY ARTERY BYPASS GRAFTING;Pilot Study - Coupler Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38998
Enrollment
20
Registered
2013-08-16
Start date
2013-09-02
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery bypass operation

Interventions

End-to-end anastomoses of the radial-LITA anastomoses with the GEM flow Microvascular coupler

Sponsors

Catharina-ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: a. Able to give informed consent able to understand the intent and clinical meaning of the study as well as its implication. b. Patients between 18 years and 70 years old c. Willing and able to have follow-up visits and examinations d. Standard Euroscore

Exclusion criteria

Exclusion criteria: a. Procedure is done as an emergency operation b. Unable to meet study requirements, i.e. mobility challenge c. Participation in any other clinical trial d. Pregnancy e. Concomitant with heart valve surgery f. History of any cardiac surgery other than PTCA and stent placement g. History of IABP within the last 30 days h. History of atrial fibrillation i. Congestive heart failure or been classified NYHA Class IV in the last 30 days j. History of bleeding disorder or history of thromboembolic disease requiring anticoagulation therapy k. Hemodynamically unstable l. History of acute or chronic dialysis m. Creatinine level of > 200 mmol/ml or 2,3 mg/dL in the last 30 days n. Documented or suspected acute systemic infection o. Need for immunosuppressive therapy p. Cerebrovascular accident within the last 2 weeks q. Allergy or other contraindication for aspirin or other anticoagulant/antiplatelet therapy r. Allergy or other contraindication for Iomeron® contrast agent s. Allergy or other contraindication for metoprolol

Design outcomes

Primary

MeasureTime frame
Primary Endpoints Efficacy a. Acute Patency: The presence of acute patency of the end-to-end radial-lita anastomoses as determined by flow measurements intraoperatively. b. Chronic Patency: The presence of patency of the end-to-end radial-lita anastomoses as determined by multislice CT - Scan at 3 months. c. Incidence of device related Adverse Events

Secondary

MeasureTime frame
x

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)